Cited by 5,198PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Open access

Bryant, Helen E., Schultz, Niklas, Thomas, Huw D., Parker, Kayan M., Flower, Dan, Lopez, Elena, Kyle, Suzanne, Meuth, Mark, Curtin, Nicola J., Helleday, Thomas·2005·Nature

DOI 10.1038/nature03443

Open this paper in CoChat — free account

Abstract

Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.

Integrity signals

Registry

Crossref · 10.1038/nature03443

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
El‐Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 689
Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse
Murcia, J. M., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., Dantzer, F., Schreiber, V., Amé, J., Dierich, A., LeMeur, M., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 629
Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks
Lindahl, T. L., Satoh, M. S., Poirier, G. G., & Klungland, A. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89089-1 · Cited by 611
PARP is important for genomic stability but dispensable in apoptosisPreprint
Wang, Z., Stingl, L., Morrison, C. G., Jantsch, M. F., Łoś, M., Schulze‐Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 401–500 of 1,021

PARPs and ADP-Ribosylation: 50 Years … and Counting
Kraus, W. L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.006 · Cited by 205
Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
Senra, J. M., Telfer, B. A., Cherry, K. E., McCrudden, C. M., Hirst, D. G., O’Connor, M. J., Wedge, S. R., & Stratford, I. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0278 · Cited by 205
DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1
Martin, S. A., McCabe, N., Mullarkey, M. J., Cummins, R., Burgess, D. J., Nakabeppu, Y., Oka, S., Kay, E. W., Lord, C. J., & Ashworth, A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.046 · Cited by 205
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Trenner, A., & Sartori, A. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01388 · Cited by 205
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Zeichner, S. B., Terawaki, H., & Gogineni, K. (2016) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s32783 · Cited by 203
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer
Muvarak, N. E., Chowdhury, K., Xia, L., Robert, C., Choi, E. Y., Cai, Y., Bellani, M. A., Zou, Y. S., Singh, Z. N., Duong, V. H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.002 · Cited by 203
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets
Mengwasser, K. E., Adeyemi, R. O., Leng, Y., Choi, M. Y., Clairmont, C. S., D’Andrea, A. D., & Elledge, S. J. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.008 · Cited by 203
Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent
Mason, J. M., Lin, D., Wei, X., Che, Y., Yao, Y., Kiarash, R., Cescon, D. W., Fletcher, G. C., Awrey, D. E., Bray, M. R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.006 · Cited by 202
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
Peasland, A., Wang, L.-Z., Rowling, E. J., Kyle, S., Chen, T., Hopkins, A. P., Cliby, W. A., Sarkaria, J. N., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 202
Self-citation
A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors
Ruiz, S., Mayor‐Ruiz, C., Lafarga, V., Murga, M., Vega-Sendino, M., Ortega, S., & Fernández-Capetillo, Ó. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.006 · Cited by 202
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Kummar, S., Ji, J. J., Morgan, R. J., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D. E., Kiesel, B. F., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 201
Linking the Cellular Functions ofBRCAGenes to Cancer Pathogenesis and Treatment
Venkitaraman, A. R. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151422 · Cited by 201
Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs
Yang, G., Nowsheen, S., Aziz, K., & Georgakilas, A. G. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.05.005 · Cited by 200
PALB2/FANCN: Recombining Cancer and Fanconi Anemia
Tischkowitz, M. D., & Xia, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1012 · Cited by 199
SPOP mutation leads to genomic instability in prostate cancer
Boysen, G., Barbieri, C. E., Prandi, D., Blattner, M., Chae, S., Dahija, A., Nataraj, S., Huang, D., Marotz, C. A., Xu, L., et al. (2015) · eLife · doi:10.7554/elife.09207 · Cited by 199
Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for CancerPreprint
Tutt, A. N. J., Lord, C. J., McCabe, N., Farmer, H., Turner, N. C., Martin, N. M. B., Jackson, S. P., Smith, G. C. M., & Ashworth, A. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.012 · Cited by 198
Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
Liao, H., Ji, F., Helleday, T., & Ying, S. (2018) · EMBO Reports · doi:10.15252/embr.201846263 · Cited by 197
Self-citation
PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification
Langelier, M.-F., Eisemann, T., Riccio, A. A., & Pascal, J. M. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.11.002 · Cited by 196
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
Han, H. S., Dieras, V. C., Robson, M. E., Palácová, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D. L., Campone, M., Telli, M. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx505 · Cited by 196
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance
Tobalina, L., Armenia, J., Irving, E., O’Connor, M. J., & Forment, J. V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.470 · Cited by 196
ADP-ribosylation from molecular mechanisms to therapeutic implications
Suskiewicz, M. J., Prokhorova, E. A., Rack, J. G. M., & Ahel, I. (2023) · Cell · doi:10.1016/j.cell.2023.08.030 · Cited by 196
Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair
Bolderson, E., Richard, D. J., Zhou, B. S., & Khanna, K. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0096 · Cited by 194
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., & Lees-Miller, S. P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0872 · Cited by 193
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 193
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
JONES, P. G., Wilcoxen, K., Rowley, M., & Toniatti, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5018237 · Cited by 192
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15273 · Cited by 191
Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy
Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190
Pathology of hereditary breast cancer
van der Groep, P., van der Wall, E., & van Diest, P. J. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0010-3 · Cited by 190
PARP Inhibition in Cancer: An Update on Clinical Development
Sachdev, E., Tabatabai, R., Roy, V. Y., Rimel, B. J., & Mita, M. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00680-2 · Cited by 190
DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints
You, Z., & Bailis, J. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.04.002 · Cited by 189
DNA damage response – A double-edged sword in cancer prevention and cancer therapy
Tian, H., Gao, Z., Li, H., Zhang, B., Wang, G., Zhang, Q., Pei, D., & Zheng, J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.038 · Cited by 189
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases
Peralta-Leal, A., Rodríguez-Vargas, J. M., Aguilar‐Quesada, R., Rodríguez, M. I., Linares, J. L., de Almodóvar, M. R., & Oliver, F. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.04.008 · Cited by 189
m5C modification of mRNA serves a DNA damage code to promote homologous recombination
Chen, H., Yang, H., Zhu, X., Yadav, T., Ouyang, J., Truesdell, S. S., Tan, J. J., Wang, Y., Duan, M.-H., Wei, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16722-7 · Cited by 189
Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break Repair
Yata, K., Lloyd, J., Maslen, S., Bleuyard, J., Skehel, M. J., Smerdon, S. J., & Esashi, F. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.12.028 · Cited by 187
The Role of Chromosomal Instability in Cancer and Therapeutic Responses
Vargas-Rondón, N., Villegas, V. E., & Rondón‐Lagos, M. (2017) · Cancers · doi:10.3390/cancers10010004 · Cited by 187
Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition
Aguilar‐Quesada, R., Muñoz‐Gámez, J. A., Martín‐Oliva, D., Peralta, A., Valenzuela, M. T., Matínez-Romero, R., Quiles, R., Murcia, J. M., de MURCIA, G., de Almodóvar, J. M. R., et al. (2007) · BMC Molecular Biology · doi:10.1186/1471-2199-8-29 · Cited by 186
CD133+ Glioblastoma Stem-like Cells are Radiosensitive with a Defective DNA Damage Response Compared with Established Cell Lines
McCord, A. M., Jamal, M., Williams, E. S., Camphausen, K. A., & Tofilon, P. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0263 · Cited by 186
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
Dent, R. A., Lindeman, G. J., Clemons, M. J., Wildiers, H. P. M. W., Chan, A., McCarthy, N., Singer, C. F., Lowe, E., Watkins, C. L., & Carmichael, J. (2013) · Breast Cancer Research · doi:10.1186/bcr3484 · Cited by 186
Discovery and Characterization of (8 S ,9 R )-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1 H -1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3 H -pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Wang, B., Chu, D., Feng, Y., Shen, Y., Aoyagi-Scharber, M., & Post, L. E. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01498 · Cited by 186
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Lee, J.-M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L. M., Zujewski, J. A., Yu, M., Gordon, N., Ji, J. J., Sissung, T. M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju089 · Cited by 185
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Lloyd, R. L., Wijnhoven, P. W. G., Ramos‐Montoya, A., Wilson, Z., Illuzzi, G., Falenta, K., Jones, G. N., James, N. H., Chabbert, C. D., Stott, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1328-y · Cited by 185
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
Rojo, F., García-Parra, J., Zazo, S., Tusquets, I., Ferrer-Lozano, J., Menéndez, S., Eroles, P., Chamizo, C., Servitja, S., Ramírez-Merino, N., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr361 · Cited by 184
Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis
Verma, N., Vinik, Y., Saroha, A., Nair, N. U., Ruppin, E., Mills, G. B., Karn, T., Dubey, V., Khera, L., Raj, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba8968 · Cited by 184
BRCA1 haploinsufficiency for replication stress suppression in primary cells
Pathania, S., Bade, S., Guillou, M. L., Burke, K. A., Reed, R., Bowman-Colin, C., Su, Y., Ting, D. T., Polyák, K., Richardson, A. L., et al. (2014) · Nature Communications · doi:10.1038/ncomms6496 · Cited by 183
Targeting the DNA Repair Pathway in Ewing Sarcoma
Stewart, E. A., Goshorn, D. R., Bradley, C. L., Griffiths, L. M., Benavente, C. A., Twarog, N. R., Miller, G. M., Caufield, W. V., Freeman, B. B., Bahrami, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.028 · Cited by 183
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A. E., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S. M., Lin, K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 183
REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps
Taglialatela, A., Leuzzi, G., Sannino, V., Cuella-Martin, R., Huang, J., Wu-Baer, F., Baer, R. J., Costanzo, V., & Ciccia, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.016 · Cited by 183
PARP inhibitors: enhancing efficacy through rational combinations
Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. Y. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 183
Aberrant RNA Splicing in Cancer and Drug Resistance
Wang, B., & Lee, N. (2018) · Cancers · doi:10.3390/cancers10110458 · Cited by 183
Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy
Lehmann, B. D., Pietenpol, J. A., & Tan, A. R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e31 · Cited by 181
Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery
Muggia, F. M., Bonetti, A. V., Hoeschele, J. D., Rozencweig, M., & Howell, S. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.7481 · Cited by 181
Poly ADP-ribose polymerase-1: An international molecule of mystery
Woodhouse, B. C., & Dianov, G. L. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.03.009 · Cited by 181
PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination–Mediated DNA Repair
Hu, Y., Petit, S. A., Ficarro, S. B., Toomire, K. J., Xie, A., Lim, E., Cao, S. A., Park, E., Eck, M. J., Scully, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0891 · Cited by 181
Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
Toledo, L. I., Murga, M., & Fernández-Capetillo, Ó. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.002 · Cited by 180
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
Min, A., Im, S., Kim, D. K., Song, S., Kim, H. J., Lee, K.-H., Kim, T., Han, S., Oh, D., Kim, T., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0534-y · Cited by 180
MutationalPatterns: the one stop shop for the analysis of mutational processes
Manders, F., Brandsma, A. M., de Kanter, J. K., Verheul, M., Oka, R., van Roosmalen, M. J., der Roest, B. R. V., van Hoeck, A., Cuppen, E. P. J. G., & van Boxtel, R. (2022) · BMC Genomics · doi:10.1186/s12864-022-08357-3 · Cited by 190
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
Sun, K., Mikule, K. W., Wang, Z., Poon, G. K., Vaidyanathan, A., Smith, G. C., Zhang, Z.-Y., Hanke, J. H., Ramaswamy, S., & Wang, J. (2018) · Oncotarget · doi:10.18632/oncotarget.26354 · Cited by 179
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Jiang, X., Li, X., Li, W., Bai, H., & Zhang, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14133 · Cited by 179
Fanconi anemia pathway–deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated
Kennedy, R. D., Chen, C. C., Stuckert, P., Archila, E. M., la Vega, M. A. D., Moreau, L. A., Shimamura, A., & D’Andrea, A. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31245 · Cited by 178
Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions
Bartz, S. R., Zhang, Z., Burchard, J., Imakura, M., Martin, M. M., Palmieri, A., Needham, R. H. V., Guo, J., Gordon, M. L., Chung, N., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01229-06 · Cited by 178
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wållberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 178
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 178
Self-citation
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Liu, J. F., Tolaney, S. M., Birrer, M. J., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E. P., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.020 · Cited by 177
Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
Hastak, K., Alli, E., & Ford, J. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4521 · Cited by 177
DNA repair deficiency as a therapeutic target in cancer
Martin, S. A., Lord, C. J., & Ashworth, A. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.016 · Cited by 176
DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy
Carrassa, L., & Damia, G. L. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.013 · Cited by 178
The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction
Langelier, M.-F., Ruhl, D. D., Planck, J. L., Kraus, W. L., & Pascal, J. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.105668 · Cited by 175
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
Turk, A. A., & Wisinski, K. B. (2018) · Cancer · doi:10.1002/cncr.31307 · Cited by 175
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 175
Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Arun, B., Bayraktar, S., Liu, D. D., Gutierrez‐Barrera, A. M., Atchley, D. P., Pusztai, L., Litton, J. K., Valero, V., Meric‐Bernstam, F., Hortobágyi, G. N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2682 · Cited by 174
Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
Liu, X., Shi, Y., Maag, D., Palma, J. P., Patterson, M. J. S., Ellis, P. A., Surber, B. W., Ready, D. B., Soni, N. B., Ladror, U. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1973 · Cited by 174
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Esposito, M. T., Zhao, L., Fung, T. K., Rane, J. K., Wilson, A., Martin, N., Gil, J., Leung, A. Y. H., Ashworth, A., & So, C. W. E. (2015) · Nature Medicine · doi:10.1038/nm.3993 · Cited by 174
Genomic landscape of DNA repair genes in cancer
Chae, Y. K., Anker, J. F., Carneiro, B. A., Chandra, S., Kaplan, J. B., Kalyan, A., Santa-Maria, C. A., Platanias, L. C., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8196 · Cited by 174
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Toft, D. J., & Cryns, V. L. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0164 · Cited by 173
Rational Design of Human DNA Ligase Inhibitors that Target Cellular DNA Replication and Repair
Chen, X., Zhong, S., Zhu, X., Dziegielewska, B., Ellenberger, T., Wilson, G. M., MacKerell, A. D., & Tomkinson, A. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6636 · Cited by 173
XRCC1 protein; Form and function
Caldecott, K. W. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102664 · Cited by 176
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
Murai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.009 · Cited by 172
Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy
Schrempf, A., Slyšková, J., & Loizou, J. I. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.09.007 · Cited by 172
PARP inhibition impedes the maturation of nascent DNA strands during DNA replication
Vaitsiankova, A., Burdová, K., Sobol, M. A., Gautam, A., Benada, O., Hanzlíková, H., & Caldecott, K. W. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00747-1 · Cited by 172
B-aggressive Lymphoma Family Proteins Have Unique Domains That Modulate Transcription and Exhibit Poly(ADP-ribose) Polymerase Activity
Aguiar, R. C. T., Takeyama, K., He, C., Kreinbrink, K., & Shipp, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505408200 · Cited by 171
Mechanisms of Genomic Instability in Breast Cancer
Duijf, P. H. G., Nanayakkara, D. M., Nones, K., Srihari, S., Kalimutho, M., & Khanna, K. K. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.04.004 · Cited by 171
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Kim, D.-S., Camacho, C. V., & Kraus, W. L. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00557-3 · Cited by 172
Cancer research: past, present and future
Cao, Y., DePinho, R. A., Ernst, M., & Vousden, K. H. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3138 · Cited by 170
Germline Brca2 Heterozygosity Promotes Kras -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer
Skoulidis, F., Cassidy, L. D., Pisupati, V., Jonasson, J. G., Bjarnason, H., Eyfjord, J. E., Karreth, F. A., Lim, M., Barber, L. M., Clatworthy, S. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.015 · Cited by 169
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy
Xu, Y., & Her, C. (2015) · Biomolecules · doi:10.3390/biom5031652 · Cited by 169
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo‐Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 169
Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W. M., O’Connor, M. J., Vrieling, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0571 · Cited by 168
Structural Implications for Selective Targeting of PARPs
Steffen, J. D., Brody, J. R., Armen, R. S., & Pascal, J. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00301 · Cited by 168
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Liu, Y., Burness, M. L., Martin-Trevino, R., Guy, J., Bai, S., Harouaka, R. A., Brooks, M. D., Li, S., Fox, A. L., Luther, T. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1348 · Cited by 168
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 168
The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination
Zhao, W., Wiese, C., Kwon, Y., Hromas, R., & Sung, P. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111058 · Cited by 169
Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype
Giuli, M. V., Giuliani, E., Screpanti, I., Bellavia, D., & Checquolo, S. (2019) · Journal of Oncology · doi:10.1155/2019/8707053 · Cited by 168
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Oplustilova, L., Wolanin, K., Mistrík, M., Kořínková, G., Šimková, D., Bouchal, J., Lenobel, R., Bártková, J., Lau, A., O’Connor, M. J., et al. (2012) · Cell Cycle · doi:10.4161/cc.22026 · Cited by 167
Poly(ADP-ribose) makes a date with death
Heeres, J. T., & Hergenrother, P. J. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.08.038 · Cited by 167
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 168
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Lev, S. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191055 · Cited by 172
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 166
Biomarkers in triple negative breast cancer: A review
Yadav, B. S. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i6.252 · Cited by 166
PolyADP‐ribosylation and cancer
Miwa, M., & Masutani, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00567.x · Cited by 165

Authors: Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T.
Affiliations: University of Sheffield (GB)
Stockholm University (SE)
Newcastle University (GB)
Corresponding author: Helleday, Thomas
ORCID: Bryant, Helen E.
Thomas, Huw D.
Curtin, Nicola J.
Helleday, Thomas
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2005-04-14
Volume: 434
Issue: 7035
Pages: 913-917
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature03443
OpenAlex: W2009007206
Cited by: 5,198
References: 26
Citations by year: 2026: 213 · 2025: 256 · 2024: 286 · 2023: 355 · 2022: 355 · 2021: 396 · 2020: 388 · 2019: 282 · 2018: 290 · 2017: 273 · 2016: 265 · 2015: 230 · 2014: 243 · 2013: 223 · 2012: 213
FWCI: 56.59
Type: journal article
Language: en
Update notices: erratum (2007-05-17)
Open access: green
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Cancer Institute (F31CA260794)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, BRCA2 deficiency, homologous recombination, synthetic lethality, breast cancer, PARP1, DNA repair, replication fork collapse, single-strand breaks, γH2AX foci, RAD51 foci, base excision repair
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Benzodiazepines, DNA Damage, DNA Repair, DNA Replication, Mice, Nude, Neoplasms, Poly(ADP-ribose) Polymerases, Xenograft Model Antitumor Assays, Genes, BRCA2, BRCA2 Protein, Cell Line, Tumor, Mice, Azulenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks